Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · MEDICAMEQ

MEDICAMEN BI

HealthcarePharmaceuticals & Biotechnology₹396 cr market cap
₹287.40 ▼ -0.81% today As of 19 Nov 2026
52-week low ₹219.8852-week high ₹415.95

-30.3% from the 52-week high · +31.8% above the low

Medicamen Biotech Ltd. engages in the manufacture and marketing of pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm is engaged in manufacturing pharmaceutical formulations products. The firm manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The firm is primarily focused on oncology therapeutics. The firm is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. The firm's oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, Nilotinib HCI, Oxaliplatin, Pazopanib, Pomalidomide and Tegafur. The firm has two manufacturing plants at Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The firm's wholly owned subsidiary is OPAL Pharmaceuticals Pty Ltd.

The short version. MEDICAMEN BI reported revenue of ₹48 crore for Jun 2026, up 11.6% from a year earlier. Net profit was ₹2 crore (up 0.0% year on year). Return on equity was 3.5% in Mar 2026. Promoter holding was 40.46% in Sep 2026, down 2.53 points over 8 quarters.

1 · The price

How has the stock traded?

MEDICAMEN BI trades 30.3% below its 52-week high and 31.8% above its 52-week low.

Change over period: —

1M+6.5%
3M+26.7%
6M+5.6%
1Y-27.5%

2 · The business

Is it growing?

Sales, year on year+11.6%

Jun 2026 revenue of ₹48 cr.

Profit, year on year+0.0%

Jun 2026 net profit of ₹2 cr.

Net margin4.4%

0.6 pts lower than a year earlier.

3-year growth-13.4% profit

Revenue compounded at 11.9% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4861474743304545
Net profit24232231
Net margin %4.46.44.75.75.08.26.53.3
EPS (₹)1.562.841.611.971.591.92.31.15

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue198163179141115113126
Net profit1071115151213
Net margin %4.94.46.110.512.910.810.6
EPS (₹)7.115.598.6411.7312.199.9310.88

3 · The quality

How well does it turn capital into profit?

Return on equity was 3.5% in Mar 2026; debt to equity is 0.17.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %3.53.35.57.7
Return on capital %5.56.08.610.2
EBITDA margin %11.311.913.518.4
Net margin %4.84.26.010.4

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR11.9%12.1%
Profit CAGR-13.4%-4.5%
Debt to equity0.17
Interest cover4.4x
Current ratio2.54
P/E ratio30.6

4 · The owners

Who holds it, and are they adding?

Promoter holding40.46%

Down 2.53 pts over 8 quarters.

Foreign institutions4.49%

Up 4.44 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter42.9943.1640.4640.4640.4640.4640.4640.46-2.53
FII0.050.1200.060.020.10.074.49+4.44
DII0.870.690.640.590.4400.40-0.87
Public56.0455.9858.8458.8559.0359.3959.0255.0-1.04

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.01% of NAV
  • Bandhan BSE Healthcare Index Fund0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for MEDICAMEN BI are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about MEDICAMEN BI

What is the MEDICAMEN BI share price?

MEDICAMEN BI (MEDICAMEQ) last closed at ₹287.40, down 0.81% on the day. Its 52-week range is ₹219.88 to ₹415.95.

What is the market cap of MEDICAMEN BI?

MEDICAMEN BI has a market capitalisation of about ₹396 crore. Its price-to-earnings ratio is 30.6.

How are MEDICAMEN BI's latest results?

MEDICAMEN BI reported revenue of ₹48 crore for Jun 2026, up 11.6% from a year earlier. Net profit was ₹2 crore (up 0.0% year on year). Return on equity was 3.5% in Mar 2026. Promoter holding was 40.46% in Sep 2026, down 2.53 points over 8 quarters.

Who owns MEDICAMEN BI?

As of Sep 2026, shareholding was: Promoter 40.46%, FII 4.49%, Public 55.0%.

How many mutual funds hold MEDICAMEN BI?

2 mutual fund schemes held MEDICAMEN BI in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 19 Sep 2025 · Final Dividend - Rs. 1
  • 19 Sep 2024 · Final Dividend - Rs. 1
  • 20 Sep 2023 · Final Dividend - Rs. 1
  • 19 Sep 2022 · Final Dividend - Rs. 1
  • 16 Sep 2021 · Final Dividend - Rs. 1
  • 17 Sep 2020 · Final Dividend - Rs. 0.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.